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Diagnosis of cutaneous melanoma requires accurate differentiation of true malignant tumors from highly atypical
lesions, which lack the capacity to develop uncontrolled proliferation and to metastasize. We used melanoma
markers from previous work to differentiate benign and atypical lesions from melanoma using paraffin-embedded
tissue. This critical step in diagnosis generates the most uncertainty and discrepancy between dermatopathologists.
A total of 193 biopsy tissues were selected: 47 melanomas, 48 benign nevi, and 98 atypical/suspicious, including 48
atypical nevi and 50 melanomas as later assigned by expert dermatopathologists. Performance for SILV, GDF15, and
L1CAM normalized to TYR in unequivocal melanoma versus benign nevi resulted in an area under the curve (AUC)
of 0.94, 0.67, and 0.5, respectively. SILV also differentiated atypical cases classified as melanoma from atypical nevi
with an AUC¼ 0.74. Furthermore, SILV showed a significant difference between suspicious melanoma and each
suspicious atypia group: melanoma versus severe atypia and melanoma versus moderate atypia had P-values of
0.0077 and 0.0009, respectively. SILV showed clear discrimination between melanoma and benign unequivocal cases
as well as between different atypia subgroups in the group of suspicious samples. The role and potential utility of
this molecular assay as an adjunct to the morphological diagnosis of melanoma are discussed.
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INTRODUCTION
Cutaneous melanoma is the malignancy with the fastest
growing incidence in the United States, with an annual
percentage increase of 2.8% in the last two decades (SEER,
2008), and reaching epidemic proportions in some parts of
the world. It is estimated that 62,000 persons will be
diagnosed with melanoma in 2008 in the United States,
among which 8,200 will die of this disease (SEER, 2008).
Although UV exposure may have a certain role in the
pathogenesis of melanoma, other unknown factors appear to
be involved, making the prevention of this tumor an
unaccomplished goal. In the face of the rising incidence of
melanoma cases, accurate diagnosis is of great importance.
Moreover, identification of metastatic potential represents a
high priority for the dermatopathologist and for the multi-
disciplinary team of clinicians providing treatment.
To address this challenge, dermatopathologists are cur-
rently using a standard of care, which relies on direct
histological and immunohistological exam. This procedure is
based on using a microscope and the current, empirically
derived pathological guidelines.
Attempts to differentiate melanoma from benign melano-
cytic lesions have focused on the use of dermoscopy (Carli
et al., 2004) and the use of computer-assisted imaging
methods such as multi-spectral optical reconstruction (Wang
and Dhawan, 2008). However, the clinical results reported
have yet to achieve the performance level required to show
an improvement in clinical practice.
Present research focuses on providing a valuable adjunct
of the histopathological exam for diagnosing melanoma. We
have translated our previous work that identified melanoma-
specific markers (Talantov et al., 2005) to clinical utility using
paraffin-embedded tissue. This setting is where discrepancies
between the opinions of dermatopathologists occur.
RESULTS
Patient clinical and pathological characteristics
204 FFPE skin biopsy tissue specimens were selected from
patients with primary melanocytic skin lesions diagnosed at
Georgetown University Hospital. The patient series included
specimens with 102 unequivocal features of invasive
melanoma or benign nevi and 102 specimens with various
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degrees of cellular atypia. These atypical specimens were
initially classified as suspicious/atypical and subsequently
resolved by expert dermatopathologists as atypical nevi or
malignant melanoma. Two patient samples were excluded
because of insufficient RNA yield (less than 350 ng) after a
sample preparation step. An additional nine RNA samples
were excluded due to the failure of the PCR control. The final
sample set eligible for analysis consisted of 193 biopsy tissues
(95% of the original sample set) representing 47 melanomas,
48 benign nevi and 98 atypical/suspicious, including 48
atypical nevi and 50 melanomas as assigned by dermato-
pathologists. A summary of the pathological and clinical
characteristics of the melanoma samples is shown in Table 1.
Samples were ordered from most benign to most
malignant cases based on the provided clinical data by
pathology. Using a histological diagnosis, we created five
major categories: advanced melanoma, melanoma, severe
atypia, moderate atypia, and benign nevi, with each of the
193 samples fitting into one of these groups. Lentigo maligna
melanoma, melanoma in situ, and superficial invasive
melanomas were combined into a single melanoma category.
We added two sets of melanomas with advanced features
(superficial spreading with T2 and greater stage and nodular
or metastatic) into an advanced melanoma group. A binary
classification was based on splitting advanced melanomas
and melanomas into malignant, and the remaining classes as
benign. This stratification contained 97 malignant cases with
47 unequivocal and 50 severely atypical lesions classified
later as melanomas, and 96 benign cases representing 48
benign and 48 atypical nevi. All further data analysis
described in this paper is presented for unequivocal cases
classified into one of the three groups: advanced melanoma,
melanoma and benign and for equivocal cases classified into
one of the four groups: advanced melanoma, melanoma,
severe, and moderate atypia (Table 1).
All melanoma samples were collected using one of three
different surgical techniques, namely: excisional, punch or
shave biopsy, depending on the size of the lesion, its depth,
and the physician’s judgment. The distribution by type of
biopsy and yields of extracted RNA for the three biopsy types
are presented in Tables 2a and b, respectively. The sample
collection comprised of 52% shave, 32% excisional and 16%
punch biopsies. Interestingly, median RNA yields, correspond-
ing to a total average of 10.5, 4.5, and 6 slides, were equivalent
among all three types of biopsies, as indicated in Table 2b.
Reverse transcription-PCR assay
Our preliminary results (Talantov et al., 2005) based on
microarray analysis and confirmatory RT-PCR data, indicated
that a set of markers, such as GDF15, SILV, and L1CAM,
could potentially differentiate fresh frozen tissues containing
benign and malignant melanocytes. Based on gene expres-
sion profiling with the Affymetrix U133A array, we selected
33 out of 439 upregulated genes in melanoma with410-fold
overexpression relative to benign specimens. These genes
included L1 cell adhesion molecule (L1CAM), silver homolog
(SILV, me20m, gp100) and GDF15 (MIC-1, PLAB) as well as
novel genes, such as NTRK3, cathepsin B (CTSB), osteopontin
(SSPP1), and capping protein. Further we selected the genes
with the highest overexpression fold (NTRK3, GDF15, and
L1CAM) for quantitative real-time RT-PCR validation of
microarray data. As a result of confirmatory runs, we
identified GDF15 and L1CAM as the best combination, on
Table 1. Patient data summary by pathology
Patient
characteristic
Advanced
melanoma Melanoma
Severe
atypia
Moderate
atypia
Benign
nevi
Mean age 59 51 42 40 42
Gender
Female 8 35 20 8 33
Male 6 48 15 5 15
T Stage (thickness)
Tis 21
T1 (o1mm) 1 62
T2 (1.01–2mm) 7
T3 (2.01–4mm) 3
T4 (44mm) 1
M 2
Diagnosis
Superficial
spreading melanoma
6 50
Nodular melanoma 5
Melanoma in situ 21
Lentigo maligna 11
Melanoma other 3 1
Compound nevus 31
Inflamed compound
nevus
13
Intradermal nevus 4
Atypical nevus
severe atypia
2
Compound nevus
severe atypia
29
Compound nevus
moderate atypia
13
Junctional nevus
severe atypia
4
Total n per category 14 83 35 13 48
Unequivocal
melanoma, n=47
12 35
Atypical melanoma,
n=50
2 48
Unequivocal
benign, n=48
48
Atypical nevi, n=48 35 13
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a complementary basis, to separate melanoma from benign/
normal tissues in our study (Talantov et al., 2005).
In this paper we describe results using paraffin-embedded
tissue samples in a larger patient population with a
significantly different T stage representation from our initial
study (Talantov et al., 2005). In the primary skin biopsy
sample set (Table 1) 84 out of 97 cases were early stage
tumors (Tis and T1). This is representative for the melanomas
encountered in a general clinic patient population, as
compared with our previously published data in fresh frozen
tissue samples that contained 76% advanced tumors (T2 and
greater, and metastatic cases). We used quantitative RT-PCR
assays consisting of the aforementioned melanoma-specific
gene markers and a control gene marker, tyrosinase (TYR).
Melanoma-specific markers were used to identify the
presence of malignant melanocytes. TYR was used as a
melanocyte-specific marker to control for melanocyte con-
tent in primary skin biopsies.
Up to five primer/probe sets were designed for each of the
specific marker candidates. TaqMan primers and probes were
designed to span intronal sequences, so that assays would not
generate false positives from the detection of genomic DNA. All
primer/probe sets were pre-screened on a set of 20 total RNA
specimens isolated from 10 melanoma and 10 benign nevi FFPE
tissues from a commercial vendor, Oncomatrix. The best
performing primer-probe set was selected for each of the four
markers. The sequences are listed in Supplementary Table S1.
For clear-cut (unequivocal) cases, increased expression
was shown in melanoma compared with benign lesions for
the three melanoma-specific markers (Table 3, Figure 1a).
Significant differential expression was observed for SILV and
GDF15 between benign nevi and melanoma samples in
clear-cut (unequivocal) cases (2.8- and 1.2-fold with P-values
o0.001 and 0.003, respectively). However, L1CAM showed
much less differentiation with a fold change of 0.2 and no
statistical significance for the difference (P¼ 0.47) between
benign and malignant clear-cut cases (Figure 1a). Thus, this
marker was excluded from further analysis. SILV showed the
best performance with a linear response across the three
patient groups (advanced melanoma, melanoma, and benign
cases), representing continuously changing degrees of disease
status as defined by pathology.
Next, we assessed the performance of SILV and GDF15 for
differentiation between clear-cut melanomas and benign nevi
using a univariate ROC curve analysis. AUC values were
found to be 0.94, and 0.67, respectively (Figure 1b). Based on
multivariate analysis with a linear regression model, the
combination of SILV and GDF15 did not improve the assay
performance beyond the AUC of 0.94 in the clear-cut cases.
Therefore, GDF15 was not pursued further for analysis of
suspicious (equivocal cases). Finally, normalization to TYR
improved the performance of SILV to 0.94 compared with
0.78 when using raw Ct values.
We further assessed the performance of SILV by compar-
ing all suspicious cases to the unequivocal benign cases. The
average delta- Ct of SILV in the equivocal samples in each
group by histology (excluding advanced melanomas since
n¼2) was compared with the average delta- Ct of the
unequivocal benign group. The average delta- Ct values and
P-values for t-test comparisons to the unequivocal benign
samples are listed in Table 4. Importantly, SILV had a
significant difference between suspicious melanoma and
each suspicious atypia group: melanoma versus severe atypia
with a P-value¼0.0077 and melanoma versus moderate
atypia with a P-value¼0.0009. Figure 1 reconfirms our
findings that SILV is the leading marker that shows clear
Table 2a. Samples distribution by type of biopsy
Diagnosis by pathology Excision Punch Shave Total
Melanoma 21 7 23 51
Benign 6 4 41 51
Suspicious/atypical 39 22 41 102
Total 66 (32%) 33 (16%) 105 (52%) 204 (100%)
Table 2b. RNA yields for three types of biopsies
Biopsy type No. (%) Median size Section no. Median RNA yield, ng Range, ng
Excision 66 (32) 13 10.58 3–6 1,360.6 496–26,879
Punch 33 (16) 8 7 3 6 1,534.1 397–7,368
Shave 105 (52) 7 6 1.5 9–12 1,400.4 318–12,140
Table 3. Normalized delta Ct values for three melanoma-specific markers in unequivocal cases
Marker normalized
to TYR
Advanced
melanoma Melanoma
Benign
nevi
P-value, benign
versus malignant
AUC, classification as
benign or malignant
L1CAM 6.85 7.5 7.66 0.47 0.49
SILV 1.18 2.09 4.93 o0.001 0.94
GDF15 5.02 7.17 8.34 0.003 0.67
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discrimination between melanoma and benign unequivocal
cases as well as between different atypia subgroups in the
suspicious group of tissue samples.
DISCUSSION
The histological evaluation of melanocytic lesions is subject to
considerable variation in opinion between expert dermato-
pathologists. In a recent study, investigators evaluated the
concordance of opinions of two dermatopathologists in an
academic setting consulted for difficult cases of melanocytic
neoplasms. In such situations directly impacting patient
management, complete agreement was reached only in
54.5% of cases, whereas in 25% of histopathological samples
the two diagnoses were highly discordant (Lodha et al., 2008).
Along with the intrinsic constraints of the morphological
exam stands, we currently lack other methods to reliably
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Figure 1. SILV, GDF15, and L1CAM performance in benign and malignant skin lesions. (a and b) SILV, GDF15, and L1CAM in unequivocal melanoma
(47 patients) and benign nevi (48 patients) tissues, ROC AUC¼ 0.94, 0.67, and 0.5, respectively; (c and d) SILV in atypical cases classified as melanoma
(50 patients) and atypical nevi (48 patients) tissues, ROC AUC¼ 0.74.
Table 4. SILV performance in the suspicious samples across the different groups as compared with the baseline
unequivocal benign group
Normalized delta-Ct values P-values
Marker normalized
to TYR Melanoma
Severe
atypia
Moderate
atypia
Benign nevi,
unequivocal
Benign versus
moderate
Benign versus
severe
Benign versus
melanoma
SILV 1.7 2.49 3.15 4.93 0.002 3.35E09 9.98E16
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identify melanoma from other melanocytic lesions. The
unaided ‘‘naked eye’’ clinical recognition depends on the
clinician’s type of training and level of experience, but up to
1.3 and 3.8% of melanomas can be mistaken for benign
lesions by dermatologists and non-dermatologists, respec-
tively (Reeck et al., 1999). Even within a group of
dermatologists in a dedicated pigmentary lesion clinic, the
accuracy of correctly identifying melanoma was found to be
higher for professionals with more than 10 years of experience
than those with 3–5 years and 1–2 years of practice (accuracy
of 80, 62, and 56%, respectively) (Morton and Mackie, 1998).
Use of dermoscopy represents a technological improvement
in the diagnosis of melanoma, with a 49% increment in the
accuracy of the diagnosis over the naked eye (Kittler et al.,
2002). However, even this technique is operator-dependent,
with results no better than the ‘‘naked eye’’ being obtained by
the less experienced examiners (Kittler et al., 2002). There-
fore, the burden of diagnosing melanoma relies currently on
the pathological exam, modestly helped by the use of
immunohistological markers.
Previous progress in differentiating melanoma from benign
nevi has been focused on the case of Spitz nevi, which is
associated in 11.8% melanoma cases with a copy number
increase of HRAS by FISH. Although of good positive
predictive value, the relative infrequency and limited ability
of this genetic abnormality to address the complex spectrum
of melanocytic lesions calls for a technique with much
broader applicability to meet the clinical diagnostic demands
of differentiating melanoma from benign nevi (Bastian et al.,
2000).
In this study, we evaluated the performance of specific
gene expression markers and showed their potential utility in
improving melanoma diagnosis. However, the molecular
make-up of melanoma presents a formidable challenge.
Among multiple markers tested, none has yet proven to be
absolutely specific for the malignant state. Conversely,
significant fold differences of up to 150 times have been
found for several markers. In a previous microarray study, we
have identified the prostate differentiation factor GDF15, the
adhesion molecule L1CAM, along with other gene markers
(kinesin-like 5, osteopontin, cathepsin B, cadherin 3,
presenilin 2) as promising for melanoma detection (Talantov
et al., 2005). We applied PCR to our candidate markers and
FFPE tissues, which is the typical specimen format used for
the diagnosis of melanoma.
Our results show a progressive increase in at least two
genes that are differentially expressed in melanoma: SILV and
GDF15. The silver homolog (SILV, me20m, gp100) has a
central role in the biogenesis of melanosomes, namely the
maturation of melanosomes. The transition from stage I
melanosomes to stage II melanosomes involves an elongation
of the vesicle with the development of distinct fibrillar
structures. Although the major biological role of GDF15 is
still to be determined, differential gene expression of GDF15
in human common nevocellular nevi and melanoma
metastasis lesions was reported by de Wit et al., 2005. From
our study, based on multivariate analysis with a linear
regression model, we concluded that the addition of GDF15
did not improve SILV performance beyond the AUC of 0.94
in the clear-cut cases. Therefore, SILV was designated as the
final marker for the melanoma biopsy assay.
A significant difference was also observed between
severely atypical nevi and melanoma for SILV with a P-value
of 0.0077. This marker was applicable for the diagnosis of
both clear-cut (unequivocal) and suspicious (equivocal)
cases, the latter being the most difficult challenge for the
expert pathologists. Along with a contribution to the formal
knowledge of melanoma progression, quantification of these
changes has proven in our study the ability to individualize
cutaneous melanoma lesions.
From a dermatopathologist perspective, there is no single
criterion to determine whether a pigmented lesion is a
severely atypical nevus or has reached the threshold for
melanoma. Dermatopathologists wrestle with at least 10
separate histological features including degrees of asymme-
try, circumscription, rete ridge preservation, loss of melano-
cyte cohesion, pagetoid spread, cytological atypia, lack of
maturation, number of mytoses, dermal fibrosis, regression,
and other host response (Akerman, 1981). No single
immunohistochemical marker is able to distinguish benign
from malignant melanocytic proliferations.
The decision whether to assign a benign or a malignant
diagnosis in the setting of severe cytologic atypia where other
criteria for melanoma such as significant individual cell
intradermal pagetoid spread or mitotic activity are lacking,
weighs heavily on dermatopathologists. A numerical prob-
ability score of malignancy based on a quantitative RT-PCR
assay could be used as an objective factor to support
diagnosis. Dermatopathologitsts fear both missing a melano-
ma and being overly cautious as to assign the diagnosis of
melanoma to a dysplastic nevus. Fewer lawsuits arise from the
latter that, however, may account for the threshold for
melanoma diagnosis being lowered over the last decades. A
low score (that is, normalized gene expression level) from the
RT-PCR test, for instance, may give the dermatopathologist
objective data to support a diagnosis of dysplastic nevus when
there is a moderate degree of cytological atypia, yet one or
two dermal mitoses in the absence of significant architectural
disorder and individual cell pagetoid spread. Conversely, a
high probability score on the molecular marker scale when
associated with a lesion showing poor dermal maturation,
some architectural disorder, yet lacking severe cytological
atypia, might shift the dermatopathologist’s opinion towards
melanoma. Intermediate scores represent an area where the
diagnosis of melanoma will mostly benefit from establishing
correlations between molecular, histological, and clinical
parameters. Further studies may show that molecular markers
share a correlation with specific diagnostic features inter-
preted by dermatopathologists.
In conclusion, we have shown the potential utility of this
RT-PCR assay using melanoma-specific markers that can
reliably differentiate melanoma from non-melanoma lesions.
Quantitative differences characterize advanced lesions, with
potential implications for diagnosis and staging of melanoma.
The greater degree of difference when comparing nevi with
melanomas versus atypical nevi with melanomas, suggests a
www.jidonline.org 1891
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close correlation between observed cytological atypia and
the corresponding molecular fingerprint.
MATERIALS AND METHODS
Patient population and study design
We used 204 patient samples that underwent biopsies for pigmented
lesions diagnosed in the Dermatology Division at Georgetown
University Hospital. The study was performed with the ethical
approval of the Georgetown Institutional Review Board, and in
conformity with the provisions of the HIPAA Act and the Declaration
of Helsinki principles. Patient consent was not required under a
HIPAA waiver IRB approval.
Marker performance was assessed on the series of FFPE skin biopsy
tissue specimens from patients with primary melanocytic skin lesions
diagnosed at Georgetown University Hospital Dermatology. These
specimens included two series of patient samples: (1) unequivocal or
clear-cut invasive melanoma and benign nevi cases (n¼ 102); (2)
samples with various degrees of cellular atypia (n¼ 102). These
atypical specimens were initially classified as suspicious/atypical and
subsequently resolved by expert dermatopathologists as atypical nevi
(n¼ 48) or malignant melanoma (n¼ 50).
Total RNA isolation
Total RNA was isolated from FFPE blocks by using a standard
High Pure RNA Paraffin Kit from Roche, Mannheim, Germany (Cat
no. 3270289) with the following modifications. Paraffin-embedded
tissue samples were sectioned according to the size of the embedded
tumor (2–5mm or smaller¼ 9 10mm, 6–8mm or bigger¼
6 10 mm). Sections were de-paraffinized according to the manu-
facturer’s instructions. The isolated RNA was stored in RNase-free
water at 80 1C until use.
Single reaction RT-PCR assay
The following gene-expression markers (GDF-15, SILV, and L1CAM)
and normalization control gene TYR (melanocyte-specific control)
were tested in the melanoma biopsy assay using a single reaction
RT-PCR format on the ABI7900 platform.
Single one-step qRT-PCR assays were run in accordance with the
protocol described below. 50 ng of total RNA was used for qRT-PCR
and was carried out on an Applied Biosystems Prism 7900HT
Sequence Detection System in a 10 ml reaction. The qRT-PCR was
carried out using the TaqMan One-Step RT-PCR Master Mix
Reagents Kit (p/n 4309169). Each reaction consisted of 5.0 ml of
2 One-Step RT-PCR Master Mix, 0.5 ml of primer/probe mix,
0.25ml of 40 multiscribe enzyme, and RNase inhibitor mix,
0.25ml of dNTP, and 4 ml of 12.5 ng ml–1 total RNA. The primer/probe
mix consisted of a final concentration of 900 nM of forward and
reverse primers (see online Supplementary Table S1) and 250 nM of
fluorescent probe. The dNTP mix contained a final concentration of
20mM each of dATP, dGTP, dCTP, and dTTP. The qRT-PCR assays
were carried out using the following cycling parameters: 1 cycle at
48 1C for 30minutes (RT reaction); 1 cycle at 95 1C for 10minutes
(AmpliTaq Gold activation step); 40 cycles at 95 1C for 15 seconds
(denaturation), 60 1C for 1minute (annealing/extension).
Data analysis
The cycle threshold (Ct) values obtained from ABI7900 output files
were used for data analysis. In the single reaction assay configura-
tion, only samples that generated TYR Cto30 were analyzed. The
Ct values for each of the markers are presented as raw Ct normalized
against the melanocyte-specific marker, TYR, using the formula
shown below:
Ct ðNormalizedÞ ¼ Ct ðmarkerÞ  Ct ðTYRÞ
Diagnosis rendered by the assay was compared with expert
dermatopathological examination. To estimate assay performance,
AUC values were calculated based on ROC curve analysis using R
software package, version 2.5.0 (Team RDC www.r-project.org)).
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